The Company's investment in ChemoCentryx, Inc. (CCXI) is included in short-term available for sale investments at December 31, 2012 at a fair-value of $69.1 million. The Company's unrealized gain of $39.6 million on the investment, net of a deferred tax liability of $14.2 million, was included in accumulated other comprehensive income at December 31, 2012.
The Company did not repurchase any shares of its common stock during the quarter or six-month periods ended December 31, 2012. Approximately $127 million remains available at December 31, 2012 for the repurchase and retirement of shares under the currently open authorization.
Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements, including the expected effective tax rate, involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.
For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise
|SOURCE Techne Corporation|
Copyright©2012 PR Newswire.
All rights reserved